Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 12/2016

01-08-2016 | AdisInsight Report

Atezolizumab: First Global Approval

Author: Anthony Markham

Published in: Drugs | Issue 12/2016

Login to get access

Abstract

Atezolizumab (Tecentriq™)—a monoclonal antibody targeting programmed death ligand 1 (PD-L1 or CD274 antigen)—is being developed by Genentech as treatment for a variety of haematological malignancies and solid tumours. It been approved in the US as a second-line therapy for urothelial carcinoma and is awaiting approval as a second-line therapy for non-small cell lung cancer. This article summarizes the milestones in the development of atezolizumab leading to this first approval for urothelial carcinoma.
Literature
1.
2.
Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–7.CrossRefPubMedPubMedCentral
3.
4.
Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–20.CrossRefPubMed
5.
Petrylak DP, Powles T, Bellmunt J, et al. A phase Ia study of MPDL3280A (anti-PDL1): updated response and survival data in urothelial bladder cancer (UBC) [abstract no. 4501]. J Clin Oncol. 2015;33(Suppl).
6.
Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837–46.CrossRefPubMed
7.
Besse B, Johnson M, Janne PA, et al. Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC) [abstract no. 16LBA]. Eur J Cancer. 2015;51(Suppl 3):S717–8.CrossRef
8.
Spigel DR, Chaft JE, Gettinger SN, et al. Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1-selected patients with non-small cell lung cancer (NSCLC) [abstract no. 8028]. J Clin Oncol. 2015;33(Suppl).
9.
Camidge R, Liu SV, Powderly J, et al. Atezolizumab (MPDL3280A) combined with platinum-based chemotherapy in non-small cell Lung cancer (NSCLC): a phase Ib safety and efficacy update [abstract no. ORAL02.07]. J Thorac Oncol. 2015;10(9 Suppl 2):S176–7.
10.
Emens LA, Braiteh FS, Cassier P, et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC) [abstract no. 2859]. Cancer Res. 2015;75(15 Suppl).
11.
Adams S, Diamond J, Hamilton E, et al. Safety and clinical activity of atezolizumab (anti-PDL1) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer [abstract no. P2-11-06]. Cancer Res. 2016;76(4 Suppl).
12.
McDermott DF, Sosman JA, Sznol M, et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol. 2016;10(34):833–42.CrossRef
13.
Sznol M, McDermott DF, Jones SF, et al. Phase Ib evaluation of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) in patients (pts) with metastatic renal cell carcinoma (mRCC) [abstract no. 410]. J Clin Oncol. 2015;33(Suppl 7).
14.
Bendell J, Kim TW, Goh BC, et al. Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC) [abstract no. 3502]. J Clin Oncol. 2016;34(Suppl).
15.
Boyd Z, Smith D, Baker B, et al. Development of a PD-L1 companion diagnostic IHC assay (SP142) for atezolizumab [abstract no. B001]. Cancer Immunol Res. 2016;4(Suppl).
16.
Castellano D, Albers P, Gschwend JE, et al. A phase III study of the efficacy and safety of adjuvant atezolizumab (anti-PDL1) vs observation in patients with muscle-invasive urothelial carcinoma of the bladder (IMvigor 010) [abstract]. Eur Urol. 2016;15(3 Suppl).
17.
Herbst RS, De Marinis F, Jassem J, et al. Phase III clinical trials of atezolizumab compared with standard chemotherapy in PD-L1-selected chemotherapy-naive patients with advanced NSCLC [abstract no. 355TiP]. Ann Oncol. 2015;26(Suppl 9):i105–6.
18.
Mok TSK, Cappuzzo F, Jotte RM, et al. Phase III clinical trials of atezolizumab in combination with chemotherapy in chemotherapy-naive patients with advanced NSCLC [abstract no. 356TiP]. Ann Oncol. 2015;26(Suppl 9):ix106.CrossRef
19.
Rizvi NA, Chow LQM, Dirix LY, et al. Clinical trials of MPDL3280A (anti-PDL1) in patients (pts) with non-small cell lung cancer (NSCLC) [abstract no. TPS8123]. J Clin Oncol. 2014;32(5 Suppl).
20.
Emens L, Adams S, Loi S, et al. A phase III randomized trial of atezolizumab in combination with nab- paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mTNBC) [abstract no. OT1-01-06]. Cancer Res. 2015;76(4 Suppl).
Metadata
Title
Atezolizumab: First Global Approval
Author
Anthony Markham
Publication date
01-08-2016
Publisher
Springer International Publishing
Published in
Drugs / Issue 12/2016
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-016-0618-8

Other articles of this Issue 12/2016

Drugs 12/2016 Go to the issue

Review Article

Unmet Needs in LDL-C Lowering: When Statins Won’t Do!

AdisInsight Report

Obeticholic Acid: First Global Approval

Erratum

Erratum to: Olmutinib: First Global Approval

Adis Drug Evaluation

Diclofenac Sodium Bolus Injection (DylojectTM): A Review in Acute Pain Management

Review Article

Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients

Adis Drug Evaluation

Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection